Format

Send to

Choose Destination
Eur J Cancer. 2014 Jan;50(2):277-89. doi: 10.1016/j.ejca.2013.10.004. Epub 2013 Nov 21.

A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.

Author information

1
European Institute of Oncology, Medical Oncology, via Ripamonti 435, Milan, Italy. Electronic address: gaetano.aurilio@ieo.it.
2
European Institute of Oncology, Division of Epidemiology and Biostatistics, via Ripamonti 435, Milan, Italy.
3
European Institute of Oncology, Division of Pathology, via Ripamonti 435, Milan, Italy; University of Milan, School of Medicine, Milan, Italy.
4
European Institute of Oncology, Division of Epidemiology and Biostatistics, via Ripamonti 435, Milan, Italy; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, via Bicocca degli Arcimboldi 8, 20126 Milan, Italy.
5
European Institute of Oncology, Medical Oncology, via Ripamonti 435, Milan, Italy.
6
Second University of Naples, Medical Oncology, via Pansini 5, Naples, Italy.

Abstract

BACKGROUND:

The discordance in oestrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) status between primary and recurrent breast cancer is being intensively investigated and a large amount of data have been produced. However, results from different studies are heterogeneous and often conflicting. To highlight this issue, a meta-analysis of published data was performed.

METHODS:

A literature search was performed using Medline, and all the studies published from 1983 to 2011 comparing changes in ER, PgR and/or HER2 status in patients with matched breast primary and recurrent tumours were included. We used random-effects models to estimate pooled discordance proportions.

RESULTS:

We selected 48 articles, mostly reporting retrospective studies. Thirty-three, 24 and 31 articles were focused on ER, PgR and HER2 changes, respectively. A total of 4200, 2739 and 2987 tumours were evaluated for ER, PgR and HER2 discordance, respectively. The heterogeneity between study-specific discordance proportions was high for ER (I(2)=91%, p<0.0001), PgR (I(2)=79%, p<0.0001) and HER2 (I(2)=77%, p<0.0001). Pooled discordance proportions were 20% (95% confidence interval (CI): 16-35%) for ER, 33% (95% CI: 29-38%) for PgR and 8% (95% CI: 6-10%) for HER2. Pooled proportions of tumours shifting from positive to negative and from negative to positive were 24% and 14% for ER (p=0.0183), respectively. The same figures were 46% and 15% for PgR (p<0.0001), and 13% and 5% for HER2 (p=0.0004).

CONCLUSION:

Our findings strengthen the concept that changes in receptor expression may occur during the natural history of breast cancer, suggesting clinical implications and a possible impact on treatment choice.

KEYWORDS:

Breast cancer; Concordance; HER2; Hormone receptors

PMID:
24269135
DOI:
10.1016/j.ejca.2013.10.004
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Archivio Istituzionale della Ricerca Unimi
Loading ...
Support Center